Navigation Links
Zacks Investment Research Initiates Coverage on Viral Genetics
Date:1/28/2011

SAN MARINO, Calif., Jan. 28, 2011 /PRNewswire/ -- Viral Genetics, Inc. (Pinksheets: VRAL) announced today that Zacks Investment Research has initiated coverage of the company. Zacks Investment Research, which provides independent investment research to individual and institutional investors, has just released a comprehensive report that describes Viral Genetics in detail, along with its recommendations. This report includes information about two unique drug discovery platform technologies, Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT), as well as other important company-related information.

The report is available on the Viral Genetics' website at http://www.viralgenetics.com/investors/press-releases/ZacksReport.PDF

For a copy of the full research report, please email scr(at)zacks(dot)com with the ticker VRAL as the title.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at www.viralgenetics.com

About Zacks Small Cap Research

Founded in 1978 in Chicago, Zacks Investment Research is one of the largest independent investment research and consulting firms in the United States. The company provides individual and institutional investors with analytical tools and financial information necessary to the success of their investment process. Zacks' models continually process stock reports issued by 3,000 analysts from 150 brokerage firms.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.Contact:Haig Keledjian, Viral GeneticsT: (626) 334-5310Info(at)viralgenetics(dot)com
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Oppenheimers Investment Bank Continues Expansion -- Lance Alstodt Named Managing Director - Healthcare
8. Hologic Expands Healthcare Investment in Asia
9. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
10. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
11. HealthSport, Inc. Announces Agreement for $10 Million Investment by SMI Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: ... company that provides clinically useful molecular diagnostic tests ... entered into agreements to successfully restructure its secured ... concurrently terminate its royalty and milestone obligations. ... RedPath amounting to $9.34 million is being acquired ...
Breaking Medicine Technology:
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall ... modular industry or whose acts have had a significant impact on the careers of all ... and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
Breaking Medicine News(10 mins):